CytomX hires Mamata Gokhale as regulatory affairs head

CytomX Therapeutics Inc. (NASDAQ: CTMX) appointed Mamata Gokhale as Senior Vice President of Regulatory Affairs, according to a company statement. Gokhale will oversee the company's global regulatory strategy and engagement to support advancement of its PROBODY pipeline through clinical development.

Gokhale brings over 25 years of regulatory experience spanning early-stage clinical development through commercialization. She most recently served as VP of Global Regulatory Affairs at Perspective Therapeutics, where she led regulatory strategy for multiple oncology programs and secured expedited designations.

Prior to Perspective, Gokhale was VP of Global Regulatory Affairs at Sierra Oncology, which was acquired by GSK, where she led regulatory strategy that resulted in U.S. and European approvals of OJJAARA (momelotinib). She previously held senior regulatory roles at Actinium Pharmaceuticals and Amgen, and began her career at the U.S. Food and Drug Administration as a Clinical Pharmacologist and Reviewer.

"Mamata brings deep global regulatory expertise and a proven track record of advancing oncology assets through late-stage development, global approvals and commercialization," said Sean McCarthy, president and CEO of CytomX.

Gokhale noted that CytomX's lead program Varseta-M could potentially advance into a registrational study in late line colorectal cancer by the first half of 2027. She received her Ph.D. in Biochemistry from the University of Bombay, India and completed postdoctoral training at Johns Hopkins School of Medicine & Public Health.

CytomX develops conditionally activated biologics designed for the tumor microenvironment. The company's pipeline includes Varseta-M, an antibody-drug conjugate for metastatic colorectal cancer, and CX-801, an interferon alpha-2b cytokine for metastatic melanoma.

You May Also Be Interested In

• Provident Bank names Adriano Duarte as CFO, effective July 1
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• Silexion gets German approval for pancreatic cancer trial of SIL204